Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
25.89
-1.10 (-4.08%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Mineralys Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 38.6 | 23.82 | 14.3 | 5.23 | 2.42 | |
| Research & Development | 132.01 | 168.58 | 70.36 | 26.25 | 16.31 | |
| Operating Expenses | 170.6 | 192.4 | 84.66 | 31.48 | 18.73 | |
| Operating Income | -170.6 | -192.4 | -84.66 | -31.48 | -18.73 | |
| Interest Expense | - | - | - | - | -0.03 | |
| Interest & Investment Income | 15.95 | 14.59 | 12.76 | 1.68 | - | |
| Other Non Operating Income (Expenses) | - | 0.01 | 0 | 0 | 0 | |
| EBT Excluding Unusual Items | -154.65 | -177.81 | -71.9 | -29.8 | -18.75 | |
| Other Unusual Items | - | - | - | - | -0.66 | |
| Pretax Income | -154.65 | -177.81 | -71.9 | -29.8 | -19.41 | |
| Net Income | -154.65 | -177.81 | -71.9 | -29.8 | -19.41 | |
| Net Income to Common | -154.65 | -177.81 | -71.9 | -29.8 | -19.41 | |
| Shares Outstanding (Basic) | 68 | 49 | 36 | 5 | 5 | |
| Shares Outstanding (Diluted) | 68 | 49 | 36 | 5 | 5 | |
| Shares Change (YoY) | 39.38% | 34.13% | 600.33% | 3.67% | 7.64% | |
| EPS (Basic) | -2.29 | -3.66 | -1.99 | -5.77 | -3.89 | |
| EPS (Diluted) | -2.29 | -3.66 | -1.99 | -5.77 | -3.89 | |
| Free Cash Flow | -142.43 | -166.41 | -81.17 | -29.22 | -14.56 | |
| Free Cash Flow Per Share | -2.10 | -3.43 | -2.24 | -5.66 | -2.92 | |
| EBITDA | -170.55 | -192.36 | - | - | - | |
| D&A For EBITDA | 0.06 | 0.04 | - | - | - | |
| EBIT | -170.6 | -192.4 | -84.66 | -31.48 | -18.73 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.